Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q3 2018 Earnings Presentation
25 slides from Chugai Pharmaceutical's earnings presentation, Oct 24, 2018
Slide 1: FY2018 3Q Consolidated Financial Overview (IFRS based)
FY2018 3Q Consolidated Financial Overview (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Toshiaki Itagaki October 24, 2018
Slide 2: Forward-Looking Statements
FY2018 3Q Consolidated Financial Overview Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information a
Slide 3: 3Q Results Summary
FY2018 3Q Consolidated Financial Overview 3Q Results Summary Revenues: 426.4 billion yen (+38.8, +10.0% YoY) • Domestic sales excl. Tamiflu: despite impact from HIP revision, slight increase due to continued growth of sales of mainstay products (+0.9, +0.3%) • Overseas sales: growth of Actemra and
Slide 4: IFRS and Core Results Jan-Sep
FY2018 3Q Consolidated Financial Overview IFRS and Core Results Jan-Sep (Billions of JPY) Non-Core items Intangible assets: Amortization of intangible assets +0.9 Impairment +4.4 Others: none Core net income attributable to Chugai shareholders 74.0 (Millions of shares) Weighted average number of sha
Slide 5: Financial Overview Jan - Sep
FY2018 3Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan - Sep (Billions of JPY) Royalties and other operating income +14.8 one-time income from transfer of long- listed products on HIP list, etc. Other financial income (expense) +0.1 Exchange gains/losses +0.1 Gains/Loss
Slide 6: Sales (excl. Tamiflu) Jan - Sep
FY2018 3Q Consolidated Financial Overview Year on Year Sales (excl. Tamiflu) Jan - Sep Sales by Disease Area, Sales by Products, Year on Year Comparisons Year on Year Changes (Billions of JPY) +25.0, +7.0% 379.8 354.8 Actemra Overseas -7.1, -29.5% Rituxan (17.0) (overseas) (64.4) +15.7, +32.2% +24.1
Slide 7: Tamiflu Sales Trends
FY2018 3Q Consolidated Financial Overview Tamiflu Sales Trends 6
Slide 8: Operating Profit Jan - Sep
FY2018 3Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan - Sep (Billion of JPY) M&D R&D Royalties and -1.2 G&A other operating income -3.1 +14.8 -1.2 Gross profit from sales +15.2 Increase in gross profit from sales +15.2 Increase in export to Roche and improvement of cost
Slide 9: Financial Overview Jul - Sep
FY2018 3Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jul - Sep Increase in gross profit from sales +4.2 Increase in export to Roche and improvement of cost of sales ratio to sales Increase in royalties and other operating income +1.3 Increase in operating expenses -2.3 In
Slide 10: Financial Progress Jan - Sep
FY2018 3Q Consolidated Financial Overview vs. Forecast (Core) Financial Progress Jan - Sep Cost of sales ratio vs. Sales 2018 2018 Jan – Sep Jan – Dec Actual Forecast 50.0% 50.6% Exchange rate (JPY) 2018 2018 Jan – Sep Jan – Dec Actual* Assumption 1CHF 112.79 115.00 1EUR 130.93 133.00 1USD 109.65 11
Slide 11: Sales Progress (excl. Tamiflu) Jan – Sep
FY2018 3Q Consolidated Financial Overview vs. Forecast (Core) Sales Progress (excl. Tamiflu) Jan – Sep *1 Jan - Sep progress versus Jan – Dec. *2 Forecast for Tecentriq was officially announced on April 24, 2018. *3 Forecast for Hemlibra (domestic sales) was officially announced on July 26, 2018 *4
Slide 12: Impact from Foreign Exchange
FY2018 3Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange FX impact Jan – Sep 2018 [Reference] (Billions of JPY) Historical exchange rate to the JPY (FX impact vs. Assumption) Forecast rate -0.6 1EUR: 133JPY Revenues Sales -0.3 Royalties and other -0.3 operating inco
Slide 13: Overview of Development Pipeline
Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of R&D Portfolio Management Dept., Project & Lifecycle Management Unit Dr. Minoru Hirose October 24, 2018
Slide 14: Projects under Development (1)
Overview of Development Pipeline Projects under Development (1) (as of October 24, 2018) Phase I Phase II Phase III Filed CKI27 RG6268 / RG3502 / Kadcyla AF802 (RG7853) / RG7446 / Tecentriq - solid tumors entrectinib - breast cancer Alecensa - NSCLC (1L) - NSCLC (adjuvant) - NSCLC★ (adjuvant) GC33 (
Slide 15: Projects under Development (2)
Overview of Development Pipeline Projects under Development (2) (as of October 24, 2018) Phase I Phase II Phase III Filed RG7845 / fenebrutinib MRA (RG1569) / Actemra - rheumatoid arthritis - systemic sclerosis Autoimmune SA237 (RG6168) / satralizumab - NMOSD ★ RG7935 / prasinezumab RG7916 / risdipl
Slide 16: Development Status (1)
Overview of Development Pipeline Development Status (1) In- house ACE910 / Hemlibra® Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. Ap
Slide 17: Development Status (2)
Overview of Development Pipeline Development Status (2) In- house AF802 / Alecensa® ALK positive NSCLC (adjuvant) Started global Phase 3 study (ALINA) in August 2018 In- licensed RG7446 / Tecentriq® Early breast cancer* entered in the pipeline (Phase 3) Triple negative breast cancer (adjuvant) Start
Slide 18: Other Progress (1)
Overview of Development Pipeline Other Progress (1) In- house AF802 / Alecensa® ALK positive advanced NSCLC (1L) Approved in August 2018 (China) In- licensed Rituxan® CD20-positive chronic lymphocytic leukemia Filed in August 2018 In- licensed RG1450 / gantenerumab Early Alzheimer’s disease Started
Slide 19: Other Progress (2)
Overview of Development Pipeline Other Progress (2) In- licensed RG7596 / polatuzumab vedotin Relapsed / refractory DLBCL Started Phase 2 study in October 2018 (JP) In- house OWL833 / Oral GLP-1 agonist Type 2 diabetes License agreement* with Eli Lilly for global development and marketing in Septemb
Slide 20: SA237 / satralizumab SAkuraSky study
Overview of Development Pipeline SA237 / satralizumab SAkuraSky study Neuromyelitis optica spectrum disorder (NMOSD) Data from Phase 3 study presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 Satralizumab patient group*1 showed a statist
Slide 21: Results of Clinical Trials / Conference (1)
Overview of Development Pipeline Results of Clinical Trials / Conference (1) In- licensed RG7446 / Tecentriq® Results of IMpower132 / 133 studies (Phase 3) presented at the 2018 World Conference on Lung Cancer (WCLC) in September 2018 IMpower132: non-squamous, NSCLC (1L) Tecentriq + chemotherapy ver
Slide 22: Results of Clinical Trials / Conference (2)
Overview of Development Pipeline Results of Clinical Trials / Conference (2) Results of IMpassion130 study (Phase 3) presented at the European Society for Medical Oncology (ESMO) in October 2018 IMpassion130: Triple Negative Breast Cancer (1L) Tecentriq + chemotherapy versus chemotherapy median PF
Slide 23: Results of Clinical Trials / Conference (3)
Overview of Development Pipeline Results of Clinical Trials / Conference (3) In- licensed RG6268 / entrectinib Results of integrated analysis on Phase 1/2 studies* presented at the 2018 World Conference on Lung Cancer (WCLC) in September 2018 ROS1 fusion positive NSCLC ORR: 77.4% median DOR: 24.
Slide 24: Projected Submissions (Post PoC NMEs and Products)
Overview of Development Pipeline Projected Submissions (Post PoC NMEs and Products) as of October 24, 2018 ipatasertib Filed NME line extension (RG7440) in-house Prostate Cancer EDIROL TECENTRIQ in-licensed (ED-71) (RG7446) nemolizumab* Osteoporosis TECENTRIQ NSCLC (1L) NSCLC: non-small cell lung ca
Slide 25: Contacts: Corporate Communications Dept.
Contacts: Corporate Communications Dept. Media Relations Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp Tomoko Shimizu, Hiroshi Araki, Chisato Miyoshi, Yayoi Yamada, Shumpei Yokoyama Investor Relations Group Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail:
Chugai Pharmaceutical — Q3 2018 Earnings Presentation on 6ix